1.
Pueraria lobata Targeted Preparation Improves the Clinical Symptoms of Cervical Spondylosis by Regulating the Balance of Gut Microbiota.
Qin, Y
Computational and mathematical methods in medicine. 2022;:2136807
Abstract
BACKGROUND Nanotargeted preparations can enhance the safety and effectiveness of medication by altering the pharmacokinetic behavior of drugs in the human body, and Pueraria lobata is shown to be effective in the treatment of neck and back pain. PURPOSE This study prepared a nano-Pueraria targeted preparation, in order to analyze its effect on improving the clinical symptoms of cervical spondylosis by adjusting the balance of intestinal flora. METHODS A total of 200 patients with cervical spondylosis admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine were enrolled and divided into an observation group and a control group. The control group was given Tuina therapy, and the observation group was given nano-Pueraria targeted preparation + Tuina therapy. The clinical symptoms and intestinal microflora of the two groups were examined before intervention. RESULTS It was found that the markedly effective of treatment efficacy of the observation group (98%) was higher than that of the control group (78%) after 15 days of intervention, and the clinical symptoms were obviously fewer than those of the control group. The distribution of gut microbiota showed that there were significant differences in the composition of gut microbiota between the two groups. Compared with the control group, the abundance of Firmicutes in the observation group was significantly higher, while the abundance of Bacteroidetes and Proteobacteria was significantly lower. CONCLUSION The targeted preparation of nano-Pueraria can improve the clinical symptoms of patients with cervical spondylosis by adjusting the balance of gut microbiota.
2.
The Effects of Elgucare on Degenerated Intervertebral Disc-Induced Low Back Pain and Disc Regeneration: A Clinical Trial.
Lo, WC, Chen, YT, Chen, CC
Computational and mathematical methods in medicine. 2021;:5824956
Abstract
INTRODUCTION Chronic low back pain (LBP) has a wide range of causes. However, most cases are induced by degeneration of the lumbar intervertebral discs (IVDs), and the aching caused by local compression of the affected region has considerable impacts on quality of life. This clinical trial investigated the use of Elgucare, a Chinese herbal formula, as a food supplement to reduce the pain of patients with LBP induced by degeneration of the lumbar IVDs. METHODS The study assessed patient subjective quality of life, functional limitations caused by LBP, and variations in pain. The assessment was done through the visual analogue scale (VAS) and effects on lumbar IVD thickness, water content, and bone mineral density (BMD). These parameters were evaluated before and after the administration of Elgucare or a placebo, one of which was taken by each participant for a 12-month period. RESULTS Elgucare reduced the patients' mean VAS pain score by 2.25 points and improved their mean LBP-hampered mobility as assessed by the Roland-Morris Questionnaire by 5.17 points. The results of another questionnaire indicated that Elgucare slowed the LBP-induced deterioration of patients' quality of life, while objective assessment indices obtained through X-ray and magnetic resonance imaging showed that the height and water retention of their IVDs were increased. However, the BMD results showed no improvements. CONCLUSIONS Elgucare can increase the water retention and height of IVDs and reduce LBP, thereby enhancing quality of life. Therefore, Elgucare can potentially be used as a clinical supplement.
3.
[Chinese herbal medicine for side effects of transarterial chemoembolization in liver cancer patients: a systematic review and meta-analysis].
Li, XQ, Ling, CQ
Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. 2012;(12):1341-62
Abstract
BACKGROUND Primary liver cancer is one of the most commonly seen tumors in clinical practice. Due to the stealthiness and fast progress of liver cancer, only 20% of the patients may have chance to receive operation for radical therapy. Patients seldom get benefit from systematic chemotherapy and as a result, local chemotherapy methods such as transarterial chemoembolization (TACE) have become the mainstay in the treatment of liver cancer. Compared with systematic chemotherapy, TACE produces fewer side effects and most of such side effects are caused by postembolization syndrome manifested as nausea and vomiting, abdominal pain, fever, loss of appetite, etc. OBJECTIVE In this systematic review, effects of Chinese herbal medicine (CHM) in relieving side effects caused by TACE in patients with liver cancer were evaluated and meta-analysis was conducted when possible. SEARCH STRATEGY Literature search was conducted on August 23rd, 2011. The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials in the Cochrane Library, MEDLINE (Ovid SP), EMBASE (Ovid SP), and Science Citation Index Expanded, China National Knowledge Infrastructure Database, Chongqing VIP Database and Wanfang Data were searched with no time limits. INCLUSION CRITERIA Randomized clinical trials (RCTs) of CHM for TACE-induced side effects in patients with primary liver cancer were eligible for this review, regardless of blinding, language, or publication status. DATA EXTRACTION AND ANALYSIS Search results were screened to select the trials included in this review according to the inclusion criteria, and data were extracted from all the included RCTs by using a self-developed data extraction form. Assessment of risk of bias in included studies was conducted according to the Cochrane Handbook for Systematic Reviews of Intervention (Version 5.0.2): Criteria for judging risk of bias in the "risk of bias" assessment tool. Dichotomous data were expressed as risk ratio with its 95% confidence interval (CI). Continuous outcomes were expressed as mean differences with 95% CI. If there was no significant heterogeneity, the results from the fixed-effect model were presented. If the heterogeneity was not substantial, the results from the random-effect model were presented. If the heterogeneity was substantial, a meta-analysis was not performed and a narrative, qualitative summary was performed instead. In the event of substantial clinical, methodological, or statistical heterogeneity, the trial components such as patients, diseases, interventions, comparisons, and outcomes in the included trials were reviewed to decide the reason for heterogeneity. RESULTS A total of 47 RCTs were included in this review after screening the search results. Among them, 46 were in Chinese and 1 was in English; 43 were journal articles and 4 were academic dissertations; all the authors were from mainland China and all the trials were conducted in mainland China. The results of assessment of risk of bias showed that there was unclear or high risk of bias in most of the included RCTs and thus they were all with low quality. The results of systematic evaluation and meta-analysis showed that CHM was beneficial to patients with liver cancer in prolonging life expectancy, improving quality of life, reducing side effects of TACE such as nausea and vomiting, fever, liver pain, and bone marrow suppression, improving liver function indexes and immunological indexes, and enhancing objective curative effect on the tumor size. However, due to the substantial heterogeneity presented in most of the indexes, only descriptive analysis was conducted for these indexes. The results of the heterogeneity analysis showed that the causes of substantial heterogeneity may be due to the obvious difference in treatment protocol, components and dosage form of CHM, time for delivering drugs and course of treatment. CONCLUSION CHM is effective in prolonging life expectancy, improving quality of life, and reducing side effects of TACE in the treatment of liver cancer. However, due to the undesirable quality of the included RCTs and the substantial heterogeneity, most of the outcome measure indexes were failed to be meta-analyzed, and thus the significance of this review for clinical practice was limited.